Pancreatic cystic neoplasms
Pancreatic cystic neoplasms are epithelial-lined cysts of the pancreas, divided into mucin-producing lesions with malignant potential (intraductal papillary mucinous neoplasm and mucinous cystic neoplasm) and non-mucin-producing serous cystadenomas with essentially none. Most are found incidentally; imaging morphology and high-risk features (symptoms, size 3 cm or more, main duct dilation, solid component) decide between no follow-up, MRI surveillance, endoscopic ultrasound with cyst fluid analysis, and surgical resection, which is the only treatment.
- Topic reviewThe full article, organized the way the exam asks it.
- ABIM-format MCQsVignettes with an explanation for every wrong answer.
- Key factsThe numbers and thresholds worth memorizing, up front.
- AI tutorMedBrain answers the question you're stuck on.
What this article covers
- Overview
Definition: pancreatic cystic neoplasms are true, epithelium-lined cystic tumors of the pancreas, distinct from the inflammatory pancreatic pseudocyst, whose wall is granulation tissue without an epithelial lining.
- Epidemiology
Common incidental finding: cysts are found in 15% of patients undergoing abdominal imaging and are most common in older adults (over 70 years); detection is rising with use and quality of cross-sectional imaging.
- Risk factors
Main pancreatic duct involvement: the strongest predictor of malignancy; main-duct IPMN has a malignant transformation rate as high as 65%.
- Pathophysiology
Mucinous neoplasia of the ductal system: IPMN is an intraductal mucin-producing neoplasm arising from the main pancreatic duct or, more often, a side branch; main-duct disease dilates the main…
- Clinical features
Usually asymptomatic and incidental: most cysts are found on imaging performed for an unrelated reason, such as abdominal pain from another cause.
- Differential diagnosis
Pancreatic ductal adenocarcinoma with cystic features: a firm mass with cystic change, jaundice, weight loss, and new-onset diabetes; a solid component on imaging should be treated as cancer until proven otherwise (pancreatic cancer).
- Diagnosis
How the diagnosis is established: no single criteria set or definitive test exists; the cyst is classified as mucinous or non-mucinous by cross-sectional imaging morphology, then risk-stratified by…
- Management
First, decide whether the cyst is non-mucinous and benign: classic serous cystadenoma needs no further evaluation or intervention unless symptomatic, and a confirmed pseudocyst is drained only if symptomatic or infected, regardless of size.
- Complications
Invasive pancreatic adenocarcinoma: the most serious outcome, most likely from main-duct IPMN (up to 65%) and MCN; once invasive, prognosis is that of pancreatic cancer.
- Prognosis
Most cysts never become malignant: branch-duct IPMN has a low rate of malignant transformation, and serous cystadenoma has none.
- Prevention
Resect before invasion: the only preventive measure for cyst-derived cancer is resection of cysts with high-risk features (size of 3 cm or more, dilated main duct, solid component, jaundice, or…
Read the whole article
Subscribing to Internal Medicine opens every article, the full question bank and MedBrain, on the web, iPhone and Android.
Related articles
- Pancreatic pseudocyst
A pancreatic pseudocyst is an encapsulated, fluid-filled collection lacking solid debris that forms more than 4 weeks after interstitial acute or chronic pancreatitis. Diagnosis rests on contrast-enhanced CT showing a well-defined wall around fluid. Most resolve spontaneously; endoscopic transmural drainage is reserved for symptomatic, infected, or enlarging pseudocysts.
- Pancreatic cancer
Pancreatic ductal adenocarcinoma usually presents late, with painless obstructive jaundice from a head-of-pancreas mass, weight loss, and sometimes new-onset diabetes or migratory thrombophlebitis. Pancreas-protocol CT defines resectability, endoscopic ultrasound with fine-needle aspiration confirms tissue diagnosis, and only complete surgical resection with pancreaticoduodenectomy offers a chance of cure, which most patients cannot receive.
- Chronic pancreatitis
Chronic pancreatitis is irreversible fibro-inflammatory destruction of the pancreas that produces abdominal pain along with exocrine and endocrine insufficiency, most often from long-term alcohol use in adults and cystic fibrosis in children. Diagnosis rests on CT or MRI showing calcifications and ductal change, and management combines alcohol and tobacco cessation, staged analgesia, pancreatic enzyme replacement, and endoscopic or surgical drainage for ductal obstruction.
- Acute pancreatitis
Acute pancreatitis is acinar-cell autodigestion and inflammation of the pancreas, most often from gallstones or alcohol, diagnosed by the revised Atlanta criteria and graded mild, moderately severe, or severe by organ failure. Management centers on early goal-directed lactated Ringer's resuscitation, analgesia, early enteral feeding, and timed ERCP for gallstone pancreatitis with cholangitis, reserving antibiotics for confirmed infected necrosis.
- Pancreatic neuroendocrine tumors (PanNETs)
Pancreatic neuroendocrine tumors (PanNETs) are islet-cell tumors that may be functional, producing a hormone-excess syndrome such as insulinoma or gastrinoma, or nonfunctioning and detected by mass effect or incidentally. First-line treatment is surgical resection when localized, with somatostatin analogues and acid suppression used to control hormone-excess symptoms before or in place of surgery.
- Von Hippel-Lindau disease
Von Hippel-Lindau disease is an autosomal dominant tumor-suppressor syndrome in which loss of functional pVHL causes accumulation of hypoxia-inducible factor and a lifelong predisposition to hemangioblastomas, clear-cell renal cell carcinoma, pheochromocytoma, and pancreatic cysts and neuroendocrine tumors. Diagnosis is clinical or by VHL germline testing, and management is a lifelong, age-staged surveillance program combined with nephron-sparing or HIF-2 alpha-directed treatment of lesions as they arise.
- Polycystic kidney disease
Polycystic kidney disease is a genetic cystic disorder causing progressive bilateral renal cyst formation, most commonly autosomal dominant polycystic kidney disease (ADPKD) from a PKD1 or PKD2 mutation, leading to hypertension, hematuria, and end-stage kidney disease in more than half of patients by age 70. Management centers on blood pressure control with renin-angiotensin blockade and, in patients at risk for rapid progression, vasopressin V2-receptor blockade with tolvaptan.